ReviewJournal of inflammation research2022
Application of Baricitinib in Dermatology.
Review in Journal of inflammation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Pooled it
- Baricitinib as monotherapy and with topical corticosteroids in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis of dose-response.Frontiers in allergy · 2024Pooled it
- Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy.Clinics and practice · 2026Article
- Recent Advances in Vitiligo Treatment.ImmunoTargets and therapy · 2026Review
- Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review.Annals of medicine · 2025Review
- Off-Label Treatment in Inflammatory Skin Diseases-European Point of View.Journal of clinical medicine · 2025Review
- Drug Repurposing of Voglibose, a Diabetes Medication for Skin Health.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Mass Spectrometry-Based Proteomics Analysis Unveils PTPRS Inhibits Proliferation and Inflammatory Response of Keratinocytes in Psoriasis.Inflammation · 2025Article
- Baricitinib represses the myocardial fibrosis via blocking JAK/STAT and TGF-β1 pathways in vivo and in vitro.BMC cardiovascular disorders · 2025Article
- Pharmacological Management of Psoriasis: Current Landscape and Future Perspectives.Recent advances in inflammation & allergy drug discovery · 2025Review
- Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications.Journal of clinical medicine · 2024Review
- Up-and-Coming Drugs for the Treatment of Vitiligo.Annals of dermatology · 2024Review
- Review: A Contemporary, Multifaced Insight into Psoriasis Pathogenesis.Journal of personalized medicine · 2024Review
- Neuroinflammation of Microglial Regulation in Alzheimer's Disease: Therapeutic Approaches.Molecules (Basel, Switzerland) · 2024Review
- Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata.Archives of medical science : AMS · 2024Article
- Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics.Journal of clinical medicine · 2023Review
- Signaling pathways and targeted therapies for psoriasis.Signal transduction and targeted therapy · 2023Review
- Inflammation and Psoriasis: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date.Drugs in context · 2023Review
- Emerging Role of Baricitinib in Dermatology Practice: All We Need to Know!Indian dermatology online journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are four JAK subtypes: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). Small molecule Janus tyrosine kinase (JAK) inhibitors can inhibit a variety of pro-inflammatory cytokines. Baricitinib is the first generation of JAK1/2 inhibitor targeting the ATPase of JAK, which blocks the intracellular transmission of cytokines through JAK-STATs. Thus far, it has been approved for the treatment of rheumatoid arthritis (RA); however, an increasing number of studies have suggested that baricitinib can be used to treat dermatological diseases, such as atopic dermatitis (AD), psoriasis, vitiligo, and alopecia areata. Baricitinib can be a new choice for the treatment of dermatological diseases, which cannot be treated with conventional drugs. We reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata (AA) in recent 5 years including clinical trials and case reports. Among them, the application in the field of alopecia areata is the most encouraging, and we reviewed the mechanism in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.